<?xml version='1.0' encoding='utf-8'?>
<document id="11744606"><sentence text="The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies."><entity charOffset="24-35" id="DDI-PubMed.11744606.s1.e0" text="oseltamivir" /></sentence><sentence text="Oseltamivir is an ester prodrug of the active metabolite [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a potent and selective inhibitor of neuraminidase enzyme of influenza virus"><entity charOffset="0-11" id="DDI-PubMed.11744606.s2.e0" text="Oseltamivir" /><entity charOffset="18-23" id="DDI-PubMed.11744606.s2.e1" text="ester" /><entity charOffset="57-144" id="DDI-PubMed.11744606.s2.e2" text="[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate" /><pair ddi="false" e1="DDI-PubMed.11744606.s2.e0" e2="DDI-PubMed.11744606.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s2.e0" e2="DDI-PubMed.11744606.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s2.e0" e2="DDI-PubMed.11744606.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11744606.s2.e1" e2="DDI-PubMed.11744606.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s2.e1" e2="DDI-PubMed.11744606.s2.e2" /></sentence><sentence text=" Oseltamivir is rapidly hydrolyzed by hepatic carboxylesterases to Ro 64-0802, which is then exclusively excreted by glomerular filtration and active tubular secretion without further metabolism"><entity charOffset="1-12" id="DDI-PubMed.11744606.s3.e0" text="Oseltamivir" /><entity charOffset="54-64" id="DDI-PubMed.11744606.s3.e1" text="ester" /><pair ddi="false" e1="DDI-PubMed.11744606.s3.e0" e2="DDI-PubMed.11744606.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s3.e0" e2="DDI-PubMed.11744606.s3.e1" /></sentence><sentence text=" In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir"><entity charOffset="102-113" id="DDI-PubMed.11744606.s4.e0" text="oseltamivir" /></sentence><sentence text=" Crossover studies were conducted in healthy subjects in which oral oseltamivir was administered alone and coadministered with probenecid, cimetidine, or amoxicillin"><entity charOffset="68-79" id="DDI-PubMed.11744606.s5.e0" text="oseltamivir" /><entity charOffset="127-137" id="DDI-PubMed.11744606.s5.e1" text="probenecid" /><entity charOffset="139-149" id="DDI-PubMed.11744606.s5.e2" text="cimetidine" /><entity charOffset="154-165" id="DDI-PubMed.11744606.s5.e3" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e0" e2="DDI-PubMed.11744606.s5.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e0" e2="DDI-PubMed.11744606.s5.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e0" e2="DDI-PubMed.11744606.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e0" e2="DDI-PubMed.11744606.s5.e3" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e1" e2="DDI-PubMed.11744606.s5.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e1" e2="DDI-PubMed.11744606.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e1" e2="DDI-PubMed.11744606.s5.e3" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e2" e2="DDI-PubMed.11744606.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11744606.s5.e2" e2="DDI-PubMed.11744606.s5.e3" /></sentence><sentence text=" Probenecid completely blocked the renal secretion of Ro 64-0802, increasing systemic exposure (area under the curve) by 2"><entity charOffset="1-11" id="DDI-PubMed.11744606.s6.e0" text="Probenecid" /></sentence><sentence text="5-fold, but no interaction was observed with cimetidine or amoxicillin"><entity charOffset="45-55" id="DDI-PubMed.11744606.s7.e0" text="cimetidine" /><entity charOffset="59-70" id="DDI-PubMed.11744606.s7.e1" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.11744606.s7.e0" e2="DDI-PubMed.11744606.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s7.e0" e2="DDI-PubMed.11744606.s7.e1" /></sentence><sentence text=" These in vivo data show that Ro 64-0802 is secreted via an organic anion pathway, but Ro 64-0802 does not inhibit amoxicillin renal secretion"><entity charOffset="115-126" id="DDI-PubMed.11744606.s8.e0" text="amoxicillin" /></sentence><sentence text=" In vitro effects of Ro 64-0802 on the human renal organic anionic transporter 1 (hOAT1) were investigated using novel Chinese hamster ovary cells stably transfected with hOAT1" /><sentence text=" Ro 64-0802 was found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-mediated transport of p-aminohippuric acid (PAH)"><entity charOffset="122-142" id="DDI-PubMed.11744606.s10.e0" text="p-aminohippuric acid" /><entity charOffset="144-147" id="DDI-PubMed.11744606.s10.e1" text="PAH" /><pair ddi="false" e1="DDI-PubMed.11744606.s10.e0" e2="DDI-PubMed.11744606.s10.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s10.e0" e2="DDI-PubMed.11744606.s10.e1" /></sentence><sentence text=" Ro 64-0802 did not inhibit the hOAT1-mediated transport of amoxicillin"><entity charOffset="60-71" id="DDI-PubMed.11744606.s11.e0" text="amoxicillin" /></sentence><sentence text=" In contrast, probenecid effectively inhibited the transport of PAH, Ro 64-0802, and amoxicillin via hOAT1"><entity charOffset="14-24" id="DDI-PubMed.11744606.s12.e0" text="probenecid" /><entity charOffset="64-67" id="DDI-PubMed.11744606.s12.e1" text="PAH" /><entity charOffset="85-96" id="DDI-PubMed.11744606.s12.e2" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.11744606.s12.e0" e2="DDI-PubMed.11744606.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11744606.s12.e0" e2="DDI-PubMed.11744606.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s12.e0" e2="DDI-PubMed.11744606.s12.e2" /><pair ddi="false" e1="DDI-PubMed.11744606.s12.e1" e2="DDI-PubMed.11744606.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11744606.s12.e1" e2="DDI-PubMed.11744606.s12.e2" /></sentence><sentence text=" These in vitro observations are consistent with the in vivo data, validating the usefulness of the in vitro system for evaluating such drug-drug interaction" /><sentence text=" The study results demonstrate that oseltamivir has a low drug-drug interaction potential at the renal tubular level due to inhibition of hOAT1"><entity charOffset="36-47" id="DDI-PubMed.11744606.s14.e0" text="oseltamivir" /></sentence><sentence text="" /></document>